-41%

est. 2Y upside i

HealthcareSeries B

Medical language models to automate healthcare operations

Rank

#1269

Sector

Healthcare IT

Est. Liquidity

~3Y

Data Quality

Data: Medium

Latent Health presents a strong upside opportunity driven by its specialized AI in a high-growth healthcare IT market with proven customer traction and a robust competitive moat.

Last updated: February 23, 2026

Bull (35%)+200%

Latent Health achieves significant market penetration and expands its platform to new areas of hospital operations, leading to a successful acquisition or IPO at a premium valuation.

Base (40%)+50%

Latent Health continues to grow steadily, securing more health system customers and demonstrating strong product value, resulting in a moderate valuation increase.

Bear (25%)-60%

Incumbent EHR vendors or well-funded AI competitors aggressively enter the prior authorization space, slowing Latent's growth and leading to a down round or less favorable exit.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold approximately $63.1M in liquidation preferences (total funding of $13.1M prior to Series B + $50M Series B) ahead of common shareholders, representing about 21% of the assumed current $300M post-money valuation. In an exit at or below this valuation, common stock may receive significantly less or nothing.

Dilution Risk

moderate

As a Series B company, Latent Health will likely require one or more additional funding rounds before a liquidity event, which will lead to further dilution of employee equity.

Secondary Liquidity

none

Active secondary markets or tender offers are typically not available for a Series B company of this size, limiting early liquidity options for employees.

Community

Valuation Sentiment

Our model estimates -41% upside. What do you think?

Anonymous. Do not share material non-public information.


Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.